About | Free Trial

Last Update


This profile was last updated on // .

Is this you? Claim your profile.

Wrong Martin Landray?

Dr. Martin Landray J.

Professor of Medicine and Epidemiology

Oxford University

Direct Phone: +44 **********       

Oxford University

Background Information


British Pharmacological Society

Higher Education Academy

Royal College of Physicians

American Society of Nephrology

Team Member
Clinical Trials Transformation Initiative (CTTI)

Board Member
NIHR Commissioning

Advisor To the Initiative
Food and Drug Administration



University of Oxford

Web References (78 Total References)

Our team — Nuffield Department of Population Health

www.ndph.ox.ac.uk [cached]

Martin Landray

Martin Landray
Martin Landray
Martin Landray

with Professor Martin ...

www.ndph.ox.ac.uk [cached]

with Professor Martin Landray

A wealth of new and advancing technologies are changing the way we approach research in healthcare. The use of big data sets, precision medicine and machine learning mean that research studies can be bigger, cheaper and wider reaching than ever before. In this lecture, Professor Martin Landray, Deputy Director of the Big Data Institute, and Professor of Medicine and Epidemiology at the University of Oxford, considered how recent advancements in healthcare technologies have radically changed how we go about medical research, and look at how future innovations could further shape the field.
Join in on Twitter #tomorrowtech
Martin Landray is Professor of Medicine and Epidemiology within the Nuffield Department of Population Health and Deputy Director of the Big Data Institute within the Li Ka Shing Centre for Health Information and Discovery.

Professor Martin Landray ...

www.ukbiobank.ac.uk [cached]

Professor Martin Landray (University of Oxford)

Opposing were Martin ...

www.bioworld.com [cached]

Opposing were Martin Landray, professor of medicine and epidemiology, at the University of Oxford, in the U.K., and Bettina Ryll, the Uppsala, Sweden-based founder of Melanoma Patient Network Europe.

Landray countered that the current problems arise from an absence of or inadequate engineering. He cast poor interpretation and misapplication of regulations and an overly cautious approach to technology as the "enemies of innovation. He argued for a quality-by-design approach to clinical development, which builds on a culture of critical thinking, focusing efforts on essential activities and focus on errors that matter, while building broad stakeholder engagement. All of these are principles of engineering design, he said. "Our failure has been to apply those principles closely," he said. "It's not overengineering is the problem - it's forgetting to engineer is the problem."
He defended regulators, who have made valuable inputs into new development approaches, such as quality by design, risk-based management and risk-proportionate studies "All these things come out of working with regulators," he said.
"We agree that trials are too expensive, too slow, highly wasteful and do not address the questions we want," Landray said. "That's not overengineering - that's insanity."
By the close of the debate, Landray and Ryll had managed to shift the audience significantly.

Research based on small numbers of ...

futuredition.org [cached]

Research based on small numbers of patients contains too many errors, particularly when it comes to analyzing the risk factors for diseases."We crave information about large numbers of people over long periods," says Martin Landray, professor of medicine and epidemiology at the University of Oxford.

Similar Profiles

Other People with this Name

Other people with the name Landray

Paul Landray
Ford University

Ted Landray
Exeter University

Robert Landray
Gazprom Marketing & Trading Ltd

Paul Landray
RouteOne LLC

Liz Landray

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory